[go: up one dir, main page]

TR200100659T2 - 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller. - Google Patents

5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.

Info

Publication number
TR200100659T2
TR200100659T2 TR2001/00659T TR200100659T TR200100659T2 TR 200100659 T2 TR200100659 T2 TR 200100659T2 TR 2001/00659 T TR2001/00659 T TR 2001/00659T TR 200100659 T TR200100659 T TR 200100659T TR 200100659 T2 TR200100659 T2 TR 200100659T2
Authority
TR
Turkey
Prior art keywords
alkyl
treatment
carbonyl
hydrogen
nervous system
Prior art date
Application number
TR2001/00659T
Other languages
English (en)
Inventor
Reginald Adams David
Mark Bentley Jonathan
Richard Anthony Roffey Jonathan
John Hamlyn Richard
Gaur Suneel
Alexander James Duncton Matthew
Edward Paul Davidson James
John Bickerdike Michael
Anthony Cliffe Ian
Langham Mansell Howard
Original Assignee
Vernalis Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Limited filed Critical Vernalis Research Limited
Publication of TR200100659T2 publication Critical patent/TR200100659T2/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Formül (I)'i haiz bir kimyasal bilesik ve farmasötik olarak kabul edilebilir tuzlari ve önilaçlari: n 1,2 veya 3'tür; R1 ve R2 hidrojen ve alkil arasindan seçilir; R3 alkildir; R4 ila R7 hidrojen, halojen, hidroksi, alkil, aril, alkoksi, ariloksi, alkiltio, ariltio, alkilsülfoksil,alkilsülfonil, arilsülfoksil, arilsülfonil, amino, monoalkilamino, dialkilamino, nitro, siyano, karboksaldehit, alkilkarbonil, arilkarbonil, aminokarbonil, monoalkilaminokarbonil, dialkilaminokarbonil, alkoksikarbonilamino, aminokarboniloksi, monoalkilaminokarboniloksi, dialkilaminokarboniloksi, monoalkilaminokarbonilamino ve dialkilaminokarbonilamino arasindan seçilir veya R5 ve R6 birlikte karbosiklik veya heterosiklik bir halka olusturur. Ayrica bilesiklerin tedavide, özellikle merkezi sinir sistemi bozukluklarinin; merkezi sinir sistemi harabiyetinin; kalp-damar hastaliklarinin; mide bagirsak bozukluklari, sekerli diyabet ve uyku apnesinin tedavisinde ve özellikle obesite tedavisinde (DEVAMI VAR).
TR2001/00659T 1998-09-01 1999-09-01 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller. TR200100659T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9819035.8A GB9819035D0 (en) 1998-09-01 1998-09-01 Chemical compounds VII

Publications (1)

Publication Number Publication Date
TR200100659T2 true TR200100659T2 (tr) 2001-10-22

Family

ID=10838167

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2005/01110T TR200501110T2 (tr) 1998-09-01 1999-09-01 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.
TR2001/00659T TR200100659T2 (tr) 1998-09-01 1999-09-01 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2005/01110T TR200501110T2 (tr) 1998-09-01 1999-09-01 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.

Country Status (29)

Country Link
US (1) US6433175B1 (tr)
EP (1) EP1109813B1 (tr)
JP (1) JP2002523508A (tr)
KR (2) KR20070062609A (tr)
CN (1) CN1165537C (tr)
AT (1) ATE273308T1 (tr)
AU (1) AU758084B2 (tr)
BR (1) BR9913477A (tr)
CA (1) CA2341991C (tr)
CZ (1) CZ296275B6 (tr)
DE (1) DE69919364T2 (tr)
DK (1) DK1109813T3 (tr)
ES (1) ES2226430T3 (tr)
GB (1) GB9819035D0 (tr)
HR (1) HRP20010126B1 (tr)
HU (1) HUP0103333A3 (tr)
ID (1) ID28842A (tr)
IL (2) IL141659A0 (tr)
MX (1) MXPA01002101A (tr)
NO (1) NO321527B1 (tr)
NZ (1) NZ510097A (tr)
PL (1) PL346427A1 (tr)
PT (1) PT1109813E (tr)
RU (1) RU2232162C2 (tr)
SI (1) SI1109813T1 (tr)
TR (2) TR200501110T2 (tr)
WO (1) WO2000012510A1 (tr)
YU (1) YU16001A (tr)
ZA (1) ZA200101457B (tr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
GB9918965D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
US6818639B2 (en) 2000-07-21 2004-11-16 Biovitrum Ab Pharmaceutical combination formulation and method of treatment with the combination
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
JP4204315B2 (ja) 2000-11-20 2009-01-07 ビオヴィトルム・アクチボラゲット(プブリクト) セロトニン5−ht2レセプターのアンタゴニストとしてのピペラジニルピラジン化合物
CA2432122A1 (en) 2000-12-20 2002-08-01 Bristol-Myers Squibb Pharma Company Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
ES2291374T3 (es) * 2000-12-27 2008-03-01 F. Hoffmann-La Roche Ag Derivados de indol y su empleo como ligandos receptores de 5-ht2b y 5-ht2c.
WO2002098350A2 (en) 2001-06-01 2002-12-12 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma
CN1512879A (zh) 2001-06-01 2004-07-14 �Ƹ��� 新的芳氨基丙烷类似物及其用于治疗青光眼的用途
EP1392658A4 (en) 2001-06-01 2004-10-13 Alcon Inc NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE IN THE TREATMENT OF GLAUCOMES
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
MXPA04012711A (es) 2002-06-19 2005-03-23 Biovitrum Ab Nuevos compuestos, su uso y preparacion.
KR20050033654A (ko) * 2002-08-30 2005-04-12 알콘, 인코퍼레이티드 치환된 5-크로만-5-일-에틸아민 화합물 및 녹내장의 치료용그의 용도
EP1581209A4 (en) 2002-12-13 2009-03-11 Alcon Inc NEW BENZOPYRAN ANALOGUE AND ITS USE FOR THE TREATMENT OF GLAUKOM
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2005058911A2 (en) 2003-12-15 2005-06-30 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
JP2008518917A (ja) 2004-11-01 2008-06-05 ワイス Cns薬剤としての置換インドリジンおよび誘導体
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
AP2007004144A0 (en) 2005-03-31 2007-08-31 Pfizer Prod Inc Cyclopentapyridine and tetrahydroquinoline derivatives
FR2884252B1 (fr) * 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
BRPI0610785A2 (pt) * 2005-04-22 2016-09-13 Wyeth Corp polimorfo cristalino, processo para preparar o mesmo, forma cristalina, composição, e, métodos para tratar uma doença, distúrbios, e uma condição
EP1888585B1 (en) * 2005-05-03 2011-06-29 F. Hoffmann-La Roche AG Tetracyclic azapyrazinoindolines as 5-ht2 ligands
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
CA2657640A1 (en) * 2006-07-14 2008-01-24 Pfizer Products Inc. Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
KR101062376B1 (ko) 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
CN102964352B (zh) * 2012-11-23 2015-04-08 华中师范大学 具有生物活性的手性2,3-二氢吡咯[1,2-a]吲哚衍生物及其不对称合成方法
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3250783A (en) * 1964-09-21 1966-05-10 American Cyanamid Co Novel pyrrolo (1, 2-alpha) indoles
US4134894A (en) * 1978-05-04 1979-01-16 Warner-Lambert Company Pyrrolo[1,2-a]indole compounds
GB8416724D0 (en) 1984-06-30 1984-08-01 Sorbio Sa Lab Active compounds
US4778812A (en) * 1987-06-12 1988-10-18 American Home Products Corporation 2,3-dihydro-9-methyl-1H-pyrrolo[1,2-a]indol-1-amines and derivatives thereof
GB8802127D0 (en) * 1988-02-01 1988-03-02 Glaxo Group Ltd Chemical compounds
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
WO1993018036A1 (en) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Condensed indole derivatives as 5ht4-receptor antagonists
EP0572863A1 (de) * 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
TW251284B (tr) * 1992-11-02 1995-07-11 Pfizer
CA2157671A1 (en) * 1993-03-08 1994-09-15 Kiyotaka Katsuta Medicament for treating or preventing cerebrovascular diseases
US5629427A (en) * 1993-08-26 1997-05-13 Peterson; Dwight M. 2,7-diaminomitosene analogues

Also Published As

Publication number Publication date
CZ2001772A3 (cs) 2001-07-11
CZ296275B6 (cs) 2006-02-15
SI1109813T1 (en) 2005-02-28
CA2341991A1 (en) 2000-03-09
WO2000012510A1 (en) 2000-03-09
NO321527B1 (no) 2006-05-15
HRP20010126B1 (en) 2005-06-30
IL141659A0 (en) 2002-03-10
HK1034967A1 (en) 2001-11-09
ZA200101457B (en) 2002-02-21
AU5637599A (en) 2000-03-21
ATE273308T1 (de) 2004-08-15
KR20070062609A (ko) 2007-06-15
EP1109813A1 (en) 2001-06-27
CN1165537C (zh) 2004-09-08
KR100768595B1 (ko) 2007-10-18
BR9913477A (pt) 2001-10-09
AU758084B2 (en) 2003-03-13
NO20010991D0 (no) 2001-02-27
MXPA01002101A (es) 2002-08-20
EP1109813B1 (en) 2004-08-11
PL346427A1 (en) 2002-02-11
TR200501110T2 (tr) 2005-07-21
DE69919364D1 (de) 2004-09-16
HRP20010126A2 (en) 2002-02-28
ID28842A (id) 2001-07-05
RU2232162C2 (ru) 2004-07-10
JP2002523508A (ja) 2002-07-30
NO20010991L (no) 2001-04-23
HUP0103333A3 (en) 2002-07-29
KR20010079715A (ko) 2001-08-22
IL141659A (en) 2007-10-31
DE69919364T2 (de) 2005-08-04
ES2226430T3 (es) 2005-03-16
US6433175B1 (en) 2002-08-13
DK1109813T3 (da) 2004-12-20
CN1325399A (zh) 2001-12-05
YU16001A (sh) 2003-10-31
CA2341991C (en) 2009-04-07
PT1109813E (pt) 2004-11-30
GB9819035D0 (en) 1998-10-28
NZ510097A (en) 2003-06-30
HUP0103333A2 (hu) 2002-01-28

Similar Documents

Publication Publication Date Title
TR200100659T2 (tr) 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.
ATE239731T1 (de) Pyrazino(aza)indolderivate
YU69902A (sh) Novi derivati piperazina
MXPA03011981A (es) 3-fluoruro-pirrolidinas como agentes antidiabeticos.
GB0100623D0 (en) Chemical compounds IV
DE69930397D1 (de) Indazolderivate mit 5-ht2-rezeptor-aktivität
DE60014339T8 (de) Aryl- und heteroaryl-kondensierte aminoalkyl-imidazol-derivate: selektive modulatoren der gabaa-rezeptoren
NO20022976D0 (no) 2-(1H-indol-3yl)-2-okso-acetamider med antitumoraktivitet
WO2000012482A3 (en) Indazole derivatives with 5-ht2 receptor activity
WO2000017170A3 (en) N1-substituted benzopyrazoles as inhibitors of 5-ht2 receptors
ATE223379T1 (de) N-aryloxyethylaminderivate zur behandlung der depression
AP2002002595A0 (en) Heterocyclic amide derivatives.
MY123639A (en) Substituted isoquinoline derivatives and their use as inticonvulsants
PT1140919E (pt) Novos derivados de ciclohexano 1,4-dissubstituido para o tratamento da depressao
EA200501053A1 (ru) Производные 1,2,4-триаминобензола, пригодные для лечения расстройств центральной нервной системы